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We have established a mouse model for scleroderma
induced by repeated local injections of bleomycin
(BLM). Daily injection of BLM at a dose of >10 mg
per ml for 4 wk induced histologic changes of dermal
sclerosis, but not fibrosis, with thickened and homo-
genous collagen bundles and cellular infiltrates in
BALB/C mice, whereas clinical signs of scleroderma
were not apparent. In addition, lung fibrosis was also
induced preceding the cutaneous changes. Sclerotic
changes were not found in other sites of the skin
distant from the injection site. Dermal sclerosis could
also be induced by injecting BLM only every other
day. The sclerotic changes of the dermis were sustained
after ceasing BLM applications for at least 6 wk. Mast
cells gradually increased in number as the sclerotic
changes developed. Marked degranulation of mast
Systemic sclerosis (SSc) is an autoimmune disorder charac-terized by extensive fibrosis associated with increasedcollagen synthesis and accumulation, and affects the skinas well as various internal organs such as lung, heart,kidney, and gastrointestinal tract (Haynes and Gershwin,
1982; Krieg and Meurer, 1988). Scleroderma, sclerosis of the skin,
is the typical symptom of SSc, affects the quality of life of the
patients, and is resistant to all kinds of treatments. Although
numerous efforts have been undertaken to elucidate the patho-
genesis of SSc, the etiology and the initial events of SSc remain
unclear. By now, there is no animal model that exhibits all aspects
of SSc except the limited available models of the tight skin mouse
and chronic graft-versus-host disease mouse. Tight skin mouse is a
spontaneous mutant with a single gene defect on chromosome 2,
characterized by extensive connective tissue deposition in skin and
multiple internal organs (Katsuri et al, 1994). It develops cutaneous
hyperplasia with histologic and biochemical changes in the skin
similar to those of human scleroderma skin. Graft-versus-host disease
mouse develops cutaneous fibrosis, loss of dermal fat, atrophy of
dermal appendages, mast cell depletion, and a mononuclear cell
infiltration (Claman et al, 1985). UCD line 200 chickens develop
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cells was observed with elevated histamine release.
The amount of hydroxyproline in skin was significantly
increased at 4 wk of BLM treatment as compared with
that in untreated or phosphate-buffered saline-treated
mice. Anti-nuclear antibody was detected in serum of
BLM-treated mice. Transforming growth factor-b1
mRNA was detected at an early phase, while trans-
forming growth factor-b2 mRNA was strongly
expressed at 4 wk when the sclerotic features were
prominent. These results suggest that dermal sclerosis
induced by BLM closely resembles systemic sclerosis
both histologically and biochemically. Our mouse
model can provide a powerful tool of inducing dermal
sclerosis to examine the pathogenesis and the thera-
peutic approach of scleroderma. Key words: fibrosis/
mast cell/RT-PCR/sclerosis/TGF-b. J Invest Dermatol
112:456–462, 1999
fibrotic changes and produce anti-nuclear antibody (Gershwin et al,
1981; Van de Water et al, 1984; Van de Water and Gershwin,
1985). This chicken model resembles SSc regarding particularly
mononuclear cell infiltration in various organs and fibrosis of skin
and esophagus.
Bleomycin (BLM), whose side-effects include pulmonary fibrosis
or scleroderma-like conditions, is an antibiotic widely used for
cancer treatment. BLM is also well known to induce lung injury/
fibrosis in experimental animal models (Aso et al, 1976; Adamson,
1984; Chandler, 1990). In this study, we have attempted to establish
an animal model of SSc skin by subcutaneous injections of BLM.
Repeated injections of BLM induced not only skin sclerosis but
also lung fibrosis in mice. Our mouse model could provide an aid
to analyse the etiology and therapeutic strategy of scleroderma
of SSc.
MATERIALS AND METHODS
Animals Specific pathogen-free, female BALB/C mice and C3H mice
of 6 wk old (weighing about 20 g) were purchased from Japan Clea
(Tokyo, Japan) and maintained with food and water ad libitum.
Bleomycin treatment BLM (Nippon Kayaku, Tokyo, Japan) was dis-
solved in phosphate-buffered saline (PBS) at different concentrations of
1 mg per ml, 100 µg per ml, 10 µg per ml, and 1 µg per ml, and sterilised
with filtration. One hundred microliters of each concentration of BLM or
PBS were injected subcutaneously into the shaved back of the mice daily
for 1–4 wk with a 27 gauge needle. In each group, more than 10 mice
were histologically examined. In several experiments, mice were injected
only every other day.
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Histopathology and immunohistochemistry The back skin was
removed on the next day after the final injection. The skin pieces were
cut into two. One was fixed in 10% formalin solution and embedded in
paraffin, and the other half was snap-frozen in OCT compound (Miles,
Elkhart, IN) in liquid nitrogen and stored immediately at –80°C. Five
micrometer thick cryostat sections were prepared on poly L-lysin-coated
slides, and fixed with cold acetone for 10 min. To block the endogenous
peroxidase activity, the sections were treated with methanol containing
0.3% hydrogen peroxide for 15 min at room temperature and then washed
in PBS. The sections were stained using a standard avidine-biotin peroxidase
technique with anti-L3T4 monoclonal antibody (CD4, diluted in PBS,
1:200) (Seikagaku Kogyo, Tokyo, Japan), anti-Lyt 2 monoclonal antibody
(CD8, 1:200) (Pharmacia, Uppsala, Sweden), anti-mouse pan-tissue-fixed
macrophage antibody (1:100) (BM-8, Biomedicals, Switzerland), anti-stem
cell factor monoclonal antibody (1:200) (Genzyme, Cambridge, MA), anti-
transforming growth factor-β (1:250) (TGF-β) polyclonal antibody (R&D
Systems, Minneapolis, MN), and anti-decorin antibody (1:100) (generous
gift by Prof. Shinkai, Chiba, Japan). Cytokine expression of cellular
infiltrates was also examined by several anti-cytokine antibodies against
interleukin-6 (IL-6) (1:250) (Genzyme), IL-10 (1:250) (Upstate Biotech,
NY), and intercellular adhesion molecule-1 (1:250) (R&D). The sections
were developed with 3,39-diaminobenzidine solution as chromogen. They
were counterstained with hematoxylin, dehydrated, cleared, and mounted.
Negative controls were prepared by omitting the primary antibodies, and
by their substitution with a nonspecific IgG antibody at the dilution used
for the specific antibodies in this study. Dermal thickness was measured
after taking photographs under a light microscope of hematoxylin and
eosin sections.
Measurement of hydroxyproline Full-thickness punch-biopsied speci-
mens of 6 mm diameter were obtained weekly from the shaved dorsal skin
of each animal during the 4 wk of the injection and stored at –80°C.
Collagen deposition was estimated by determining the total content of
hydroxyproline in the skin. The stored skin pieces were hydrolyzed with
6 N hydrochloric acid under 110°C for 18 h according to the method
previously described (Woessener, 1961). After neutralization with sodium
hydroxide, the hydrolysates were diluted with distilled water. Hydroxypro-
fine in the hydrolysates was assessed colorimetrically at 560 nm with p-
dimethylaminobenzaldehyde. Results were expressed as micrograms of
hydroxyproline per 6 mm diameter skin pieces.
Collagen analysis of the sclerotic skin Six millimeter punch biopsied
tissues were homogenized in acetic acid at 4°C to extract collagen. One
milligram of pepsin was added to each homogenized sample and incubated
at 4°C for 24 h with shaking. The pepsin-solubilized material was collected
after removal of the insoluble residues by centrifugation at 35,000 3 g for
60 min at 4°C. Thus extracted collagen was analyzed by polyacrylamide
stacking gel electrophoresis, utilizing a 10% polyacrylamide-running gel
overlaid with a 3.5% polyacrylamide stacking gel. Following electrophoresis,
the gels were stained with Coomassie brilliant blue for identification of
pepsin-resistant collagen.
Mast cell number and plasma histamine level Mast cells were
identified by toluidine blue at a pH of 2.5, 4.1, and 7.0. Cells containing
metachromatic granules were counted in 10 random grids under high
magnification of 3400 power fields of a light microscope.
Blood samples were obtained weekly by cardiac puncture at each
week, and stored at –80°C. Plasma histamine levels were measured by
radioimmunoassay.
Enzyme-linked immunosorbent assay of serum cytokines Sera was
obtained by a cardiac puncture at 1, 2, 3, and 4 wk treatment of BLM
(n 5 5) and stored at –80°C. Serum levels of IL-4, IL-6, interferon-γ
(IFN-γ), and tumor necrosis factor-α (TNF-α) were assessed using enzyme-
linked immunosorbent assay kit (Genzyme).
Reverse transcriptase-polymerase chain reaction (PCR) of
cytokines Total RNA was extracted weekly from biopsied frozen tissues
during the 4 wk of BLM injection with RNA zol (Chinna/Biotex, Houston,
TX). RNA yield and purity was determined with spectrophotometry. Total
RNA was then diluted with sterile diethylpyrocarbonate-treated water and
stored at –80°C until use. Reverse transcriptase-PCR was performed
using the DNA Thermocycler (Program Temp Control System, PC-700,
ASTEC, Tokyo). Complementary single-stranded DNA was synthesized
from total RNA by reverse transcription. Initially, 100 ng of total
RNA (with or without prior treatment with RNAse-free DNAse) in
diethylpyrocarbonate-treated water was heated at 65°C for 5 min and
cooled rapidly. After adding 1 µl of 10 3 PCR buffer (500 mM KCL,
100 mM Tris-HCL buffer, pH 8.4, 15 mM MgCl2, and 0.01% gelatin),
1 ml of 25 mM αNTP (Takara, Tokyo, Japan), 1 µl of 10 3 hexanucleotide
mixture (Boehringer, Mannheim, Germany), 20 U of ribonuclease inhibitor
(Takara), and 3 U of RAV-2 reverse transcriptase (Takara), the mixture
was incubated at 42°C for 60 min, heated at 94°C for 5 min, and quick-
chilled on ice. The cDNA was amplified by PCR with the use of the
specific primers for mouse TGF-β1, TGF-β2, platelet-derived growth
factor (PDGF)-AA, TNF-α, and β-actin as described (Brown et al, 1995).
The upstream and downstream primers are: TGF-β1, 59 GCTAATGGTG-
GACCGCAACAACG, 39 CTTGCTGTACTGTGTGTCCAGGC;
TGF-β2, 59 CACCTCCCCTCCGAAAATGCCAT, 39 ACCCCAGGT-
TCCTGTCTTTGTGGT; PDGF-AA, 59 CACATCGGCCAACTTCCT,
39 TCACACGCCACGCACATC; TNF-α, 59 AGCCCACGTCGTAG-
CAAACCACCAA, 39 ACACCCATTCCCTTCACAGAGCAAT; β-
actin, 59 GTGGGCGCTCTAGGCACCAA, 39 CTCTTTGATGTCAC-
GCACGATTTC. The PCR conditions were optimized for each set of
primers, and PCR was performed using different numbers of cycles to
ensure that amplification occurred in a linear range. The PCR reaction
mixture contained 10 µl cDNA, 5 µl of 10 3 PCR buffer, 8 µl of
1.25 mM αNTP, 5 µl of 20 pM 59 and 39 primers, and 1.5 U of Taq
polymerase (Perkin Elmer, Cetus, Norwalk, CT). Cycle number for
amplification was 35, except for PDGF-AA (30 cycles). After amplification,
PCR products were subjected to electrophoresis on 1.7% agarose gels and
detected by ethidium bromide under UV illuminator. The intensity of
each band was measured by a densitometer (EPA-3000, Chemiway, Tokyo)
and compared with that of β-actin to quantitate the PCR products. As a
negative control, total cellular RNA without reverse transcription was used.
Detection of autoantibodies in the serum 3T3 fibroblasts were used
as the substrate to screen for the appearance of autoantibodies. After fixing
with cold acetone/methanol for 15 min, 3T3 fibroblasts were incubated
with various concentrations of mouse serum (n 5 5) for 30 min at room
temperature. They were washed with PBS and incubated with 1:100
dilution of fluorescein-conjugated goat anti-mouse IgG (Jackson Immuno-
Research Laboratory, Baltimore, MD) and examined with fluorescent epi-
illumination.
Statistical analysis Results were expressed as means 6 SD. Significance
testing was assessed by Mann–Whitney U test. A p value , 0.05 was
considered as significant.
RESULTS
Subcutaneous injections of BLM induces dermal
sclerosis Subcutaneous injections of 1 mg BLM per ml for 4 wk
induced marked dermal sclerosis in BALB/C mice, which was
histologically characterized by thickened and homogenous collagen
bundles, thickening of vascular walls, and inflammatory infiltrates,
whereas PBS-treated mice did not develop either sclerosis or fibrosis
(Fig 1A–D). Preliminary results showed no histologic differences
between males and females. Dermal sclerosis was also induced after
injection of 10 µg per ml and 100 µg BLM per ml, whereas 1 µg
BLM per ml did not cause definite sclerosis even at 4 wk. This
dermal sclerosis was sustained for at least 6 wk after cessation of
treatment (data not shown). The dermal sclerosis was also induced
by injecting BLM only every other day. Sclerosis, but not fibrosis,
was induced even in ‘‘BLM-resistant’’ BALB/C mice. In comparison
with BALB/C mice, C3H ‘‘BLM-sensitive’’ mice developed dermal
sclerosis already after 3 wk (data not shown). There was diffuse
positive staining for colloidal iron stain in the sclerotic lesional
skin, whereas only faint staining was noted in PBS-treated mice
(Fig 1E, F). Examination of the lung revealed thickened alveolar
septa with infiltration of mononuclear cells preceding the cutaneous
changes (at 1 wk) (Fig 1G); however, sclerosis was not induced in
uninjected sites of the skin, such as in toes, abdomen, and kidney
even after 4 wk of treatment (data not shown). Toluidine blue
stain (pH 2.5, 4.1, and 7.0) demonstrated increased numbers of
mast cells around sclerotic lesions. Marked degranulation was
observed especially in the early phase, prior to the increase of mast
cell numbers (Fig 1H). Positive staining for CD8, CD4, and BM-
8 was also found in the cellular infiltrates (Fig 1I, J).
Dermal thickness showed a time-dependent increase in BLM-
treated skin, and exhibited a significant difference as compared
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Figure 1. Histopathologic evaluation of dermal sclerosis in BALB/C mice. (A) Mice were treated with PBS for 4 wk (hematoxylin and eosin
stain, 350). Neither fibrosis nor sclerosis was noted. (B) Mice were treated with bleomycin (1 mg per ml) for 2 wk (hematoxylin and eosin stain, 350).
(C) Mice were treated with bleomycin (1 mg per ml) for 4 wk (hematoxylin and eosin stain, 382). Marked dermal sclerosis with thickened and
homogenous collagen bundles were induced with cellular infiltrates in the subcutaneous tissue. (D) Vascular walls were also thickened at 4 wk (hematoxylin
and eosin stain, 3400). (E) Diffuse positive staining was noted in the sclerotic lesional skin by colloidal iron (350). (F) Faint staining was noted in the
dermis in the PBS-treated mice for 4 wk by colloidal iron (350). (G) Mononuclear cell infiltrates were also prominent in the lung at 1 wk of bleomycin
treatment (1 mg per ml) (hematoxylin and eosin stain, 3260). (H) Marked degranulation of mast cells was shown by toluidine blue stain (pH 7.0) at
2 wk (3520). (I) Positive staining for BM-8 in the infiltrating mononuclear cells was seen in the subcutaneous tissue of the sclerotic skin (3260). (J)
Fewer numbers of immunoreactive cells for BM-8 were also seen in PBS-treated mice for 4 wk (3360). Scale bar: (A, B, E, F) 100 µm, (C) 60 µm, (D)
12.5 µm, (G, I) 19 µm, (H) 10 µm, (J) 14 µm.
Figure 2. Dermal thickness in BALB/C mice treated with
bleomycin. Mice were injected with 1 mg BLM per ml (dose per day,
n 5 6) (d) or PBS alone (n 5 5) (s). Dermal thickness gradually increased
as the sclerosis developed, whereas PBS-treated mice did not exhibit an
increase of dermal thickness. Significant differences were noted after 3 wk.
* p , 0.05.
with that in PBS-treated skin after 3 wk (217 6 17 vs 126 6 8.7 µm
at 4 wk, p , 0.05) (Fig 2).
Results of mast cell counts are shown in Fig 3. The numbers
of mast cells reached a peak at 3 or 4 wk after BLM administration,
and increased up to 2-fold as compared with untreated mice
(48.5 6 12.8 vs 23.0 6 8.6 per mm2, p , 0.05) or more than 1.5
Figure 3. Changes of mast cell numbers and histamine levels during
BLM treatment. The number of total and degranulated mast cells was
quantitated by identification of toluidine blue stain (pH 7.0) and represents
mean of six mice 6 SD. Total mast cell number (d) was gradually increased
as the sclerotic lesions were induced, whereas degranulated mast cell
number (s) showed its peak at 2 wk of bleomycin treatment. Plasma
histamine level (j), measured by radioimmunoassay, was elevated when
the mast cell begins degranulation.
times as compared with PBS-treated mice (29.3 6 9.4, p , 0.05)
at 4 wk. The numbers of degranulated mast cells increased more
rapidly, and peaked at 2 wk. Elevation of plasma histamine level
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Figure 4. Biochemical analysis of bleomycin-induced sclerotic
dermis in BALB/C mice. (A) Hydroxyproline assay by 6 mm punch
biopsy skin tissue. BALB/C mice were given 1 mg bleomycin per ml or
PBS subcutaneously for 4 wk and killed the next day after the final
treatment. Skin hydroxyproline content was measured as outlined in
Materials and Methods. At 4 wk, bleomycin-treated mice (n 5 5) showed
a significant increased hydroxyproline content as compared with PBS-
treated (n 5 5) or control untreated mice (n 5 5) (p , 0.05). (B) Type
1 collagen content of skin tissue. Total protein extracted from 6 mm punch
biopsied skin samples obtained from BALB/C mice with 4 wk treatment
of bleomycin or PBS were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Lanes 1, 5, pepsin soluble, reductant
(1); lanes 2, 6, pepsin soluble, reductant (–); lanes 3, 7, pepsin insoluble,
reductant (1); lanes 4, 8, pepsin insoluble, reductant (–). Representative
data are shown.
preceded the increment of numbers of either degranulated or
nondegranulated mast cells.
The amount of collagen is increased in the sclerotic skin In
the sclerotic skin induced by 4 wk injections of BLM, the content
of hydroxyproline was significantly increased as compared with
that in normal untreated mice and PBS-treated mice (Fig 4A).
The hydroxyproline content in the BLM-treated skin (120 6 17 µg
per 6 mm punch biopsied skin) was almost double that in the skin
of untreated mice (64 6 8 µg per 6 mm punch biopsied skin) and
PBS-treated mice (73 6 10 µg per 6 mm punch biopsied skin)
(p , 0.05 in both comparisons). Sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis analysis of pepsin-resistant collagen chains
revealed the presence and an increment of both α1 and α2 chains
of collagen, which comigrated with type I standard collagen, in
the sclerotic skin (Fig 4B).
Mononuclear cells and cytokine profile in the sclerotic
skin Mononuclear cell infiltration was observed in the sclerotic
dermis perivascularly and around the sclerotic collagen bundles.
The infiltrating mononuclear cells mainly consisted of CD4 positive
T cells and macrophages. Immunoreactive stem cell factor was
abundantly detected in the fibroblasts and mast cells in the sclerotic
skin. TGF-β was expressed diffusely in the extracellular matrix and
infiltrating mononuclear cells in the sclerotic dermis. In contrast,
Table I. Immunohistochemical characteristics of
infiltrating mononuclear cells in the lesional skin of BLM
or PBS-treated BALB/C mice.a
Cytokine/growth BLM-treated mice (wk) PBS-treated
factor
1 2 3 4 4
IL-2 – – – 1 –
IL-6 – – 1 11 –
IL-10 – – 1 111 –
TGF-β – – 11 111 –
ICAM-1 – – 1 111 –
a Staining intensity: –, no staining; 1, weak; 11, moderate; 111, strong.
Figure 5. PCR analysis of cytokine gene expression in bleomycin-
treated BALB/C mice. Mice received a subcutaneous injection of
bleomycin (1 mg per ml), and the next day of the final application the
back skin was removed. Total RNA was isolated from the lesional skin at
1, 2, 3, and 4 wk, and cDNA was prepared for the detection of TGF-β1,
TGF-β2, PDGF-AA, and TNF-α mRNA. PCR was performed as
described in Materials and Methods. –, negative control. Representative data
are shown.
Table II. Kinetics analysis of serum cytokine in the BLM
and PBS-treated BALB/C mice
Cytokine Treatment Weeks
1 2 3 4
IL-4 BLM ,5 16 6 5 20 6 6 54 6 8
(pg per ml) (1mg per ml)
PBS ,5 ,5 ,5 ,5
IL-6 BLM 45 6 10 43 6 9 38 6 11 62 6 10
(pg per ml) PBS ,5 ,5 ,5 ,5
TNF-α BLM 20 6 4 30 6 6 34 6 7 40 6 8
(pg per ml) PBS ,15 ,15 ,15 ,15
IFN-γ BLM ,5 ,5 ,5 ,5
(pg per ml) PBS ,5 ,5 ,5 ,5
decorin was hardly expressed in the sclerotic dermis. The results
of the immunohistochemical studies are summarized in Table I.
Reverse transcriptase-PCR was performed to analyze cytokine
profiles during the sclerotic process. mRNA expression of TGF-
β1 was detected at the early phase of dermal sclerosis, and that of
TGF-β2 was expressed mostly at 4 wk when the dermal sclerosis
became prominent (Fig 5). mRNA expression of TNF-α was
detected at the early phase, and that of PDGF-AA was expressed
all through the course.
Kinetics of serum cytokines during the sclerotic process are listed
in Table II. IL-6 was elevated from an early phase. Th2-type
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Figure 6. Detection of anti-nuclear antibody. 3T3 fibroblasts were
stained with a monospecific BALB/C mouse serum recognizing FITC-
goat anti-mouse IgG and examined by fluorescent microscopy. Diffuse
cytoplasmic staining, as well as punctate intranucleolar structures, was seen
using serum obtained at 4 wk with bleomycin treatment (A), and were
not seen in cases using serum of PBS-treated mice (B). Scale bar: 32 µm.
cytokines such as IL-4 and IL-6 were elevated in the circulation
during the sclerotic process.
BLM-treated mice produced autoantibodies In order to
investigate whether autoantibodles are present in BLM-treated
mice, we obtained serum from mice after 4 wk of BLM injection.
Exclusive staining of punctate intranucleolar structures as well as
diffuse cytoplasmic staining was observed on 3T3 fibroblasts using
sera of BLM-treated mice (Fig 6), whereas there was no positive
staining when similar experiments were performed using sera from
either nontreated mice or PBS-treated mice. These antibodies were
detected up to a dilution of 1:320.
DISCUSSION
In this study, we established a mouse model of sclerotic skin by
repeated subcutaneous injections of BLM. Daily injection of BLM
gradually induced dermal sclerosis with dermal thickening after
4 wk in BALB/C mice. Sclerosis was apparent only histologically,
and was hardly recognized clinically. Histologically, BLM-treated
dermis showed sclerosis with thickened, homogenous collagen
bundles, perivascular infiltrates, and thickening of the vascular
wall, which are all characteristic of histologic features of human
scleroderma skin. Immunohistochemical studies revealed that this
cellular infiltration mainly consisted of CD41 T cells, mast cells,
and macrophages. Cutaneous sclerosis persisted for up to 6 wk
after the final administration of BLM. Lung fibrosis was also induced
much earlier than the formation of dermal sclerosis; however,
histologic examination of the other sites of the skin distant from
the sites of injection, such as toes, stomach, or kidney, failed to
show any sclerosis. These results suggest that effects of BLM
injection on the formation of sclerotic skin lesions are local and
not generalized.
BLM-induced pulmonary fibrosis is a well-established histologic
and biochemical animal model, which is characterized by the
accumulation of collagen within the lung following enhancement
of collagen synthesis (Aso et al, 1976; Adamson, 1984; Chandler,
1990). Previous studies examined chronic effects of BLM on mice
when BLM was administered only once every 2 wk (Mountz et al,
1983). In their study, increased collagen fibers were demonstrated,
whereas serum antibodies were not detected. To our knowledge,
however, skin fibrosis/sclerosis using continuous injections of BLM
has not been examined in detail. One of the reasons may be that
dermal sclerosis is only histologically induced by BLM, as has been
demonstrated in this study. Our results may reflect on acute dermal
changes and it is of note that local administration of BLM caused
sclerosis, but not fibrosis. Pulmonary fibrosis has been induced in
mice in about 2 wk by a single intravenous injection of BLM
(Adamson and Bowden, 1974), in 4–8 wk by intraperitoneal
injections (Adamson and Bowden, 1979), and after a short interval
by administration through the trachea (Anider et al, 1978). The
extent of experimental lung fibrosis depends on the dose and the
route of administration of BLM as well as on the mouse strain.
C57/BL6 is a susceptible strain, whereas BALB/C is a resistant
strain (Schrier et al, 1983). In this study, we could induce sclerosis
even in the BLM-resistant BALB/C mice by injecting BLM for
4 wk at a dose of more than 10 µg per ml. Dermal sclerosis was
also induced even by alternate day’s injection of BLM for 4 wk.
In other experiments using BLM-sensitive C3H mice, sclerosis was
induced earlier, and interestingly, also with epidermal proliferation
(Yamamoto et al, manuscript in preparation).
It is of note that mast cells are increased in number as the
sclerotic lesion was induced, showing a peak at 3 or 4 wk.
Furthermore, degranulation of mast cells was observed earlier, with
a peak at 2 wk. Mast cells are abundant in the skin of tight skin
mice and exhibit prominent degranulation (Walker et al, 1985).
Inhibition of mast cell degranulation by cromolyn (Walker et al,
1987) or ketotifen (Walker et al, 1990)was associated with decreased
fibrosis in this model. As mast cells form a heterogenous population
with different developmental stages, mediator contents, ultrastruc-
ture, as well as ability to interact with their local environment
(Dayton et al, 1989), and contain many cytokines or chemical
mediators, including histamine, heparin, tryptase, proteinase, leuko-
triens, or prostaglandin D2, it is likely that secretion, activation, or
degranulation of mast cells have the potential to cause microenviron-
mental changes. Mast cells influence fibroblast behavior by mem-
brane contact (Dvorak, 1991). Recent findings demonstrated that
mast cell precursors circulate as agranular mononuclear cells and
undergo final maturation and granule synthesis after migration into
tissues in a stem cell factor-dependent manner (Church et al, 1994).
In this study, stem cell factor was expressed on fibroblasts and mast
cells especially in the sclerotic phase (data not shown). Plasma
histamine levels were also elevated during the early phase. Histamine
has a mitogenic activity for fibroblasts (Russel et al, 1977) and is a
potent modulator of collagen metabolism of fibroblasts (Hatamochi
et al, 1985). Tryptase has also been shown to be mitogenic for
fibroblasts (Ruoss et al, 1991) and stimulates the synthesis of type
I collagen in fibroblasts (Cairns and Walls, 1997; Gruber et al,
1997). Thus, interaction of mast cell granule constituents with
connective tissue cells, components of extracellular matrix, and
inflammatory cells also suggests the participation of mast cells in
active fibrosis. In scleroderma, mast cell numbers are increased,
especially in the edematous phase (Nishioka et al, 1987); however,
mast cell products alone are unlikely to be sufficient to induce
sclerosis. In our recent observation using mast cell-deficient
mice, sclerosis was also induced by injections of BLM in WBB6F1-
W/Wv mice, which may indicate that infiltrating mononuclear
cells are more important for the induction of sclerosis (Yamamoto
et al, manuscript submitted).
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It has been shown that mouse CD41 T cell clones could be
classified into distinct subsets according to their cytokine production
pattern, and it is widely accepted that the same dichotomy is
applied to human T cells. The contribution of IL-4 to scleroderma
leads to the classification of this disorder as a Th2 condition. IL-4
is produced by activated memory T cells and mast cells, both types
of cells having a significant role in the pathogenesis of scleroderma.
IL-4 stimulates fibroblast proliferation and fibroblast extracellular
matrix production, and promotes T cell adhesion to endothelial
cells, differentiation of lymphocytes, regulation of inflammatory
responses, and growth of mast cells and lymphocytes (Monroe et al,
1988; Thornhill et al, 1990; Fertin et al, 1991; Gillery et al, 1992).
Increased IL-4 production has been detected in the sera or by
activated peripheral blood mononuclear cells of patients with SSc
(Famularo et al, 1990; Needleman et al, 1992). IL-4 levels signific-
antly correlate with skin scores and are inversely associated with
the duration of the disease (Lindner and Frieri, 1991). IL-6
has also been shown to stimulate the synthesis of collagen and
glycosaminoglycans (Duncan and Berman, 1991). In vitro study has
shown that IL-4 induces the production of IL-6 by human skin
fibroblasts (Feghali et al, 1992), which suggests that these cytokines
are able to amplify the stimulating effects of collagen synthesis.
Elevated IL-6 levels have also been frequently found in sera of SSc
patients (Needleman et al, 1992). Our results regarding cytokine
production in the sera of BLM-treated mice indicate a Th2 pattern.
Accumulation of several connective tissue components has also
been studied in BLM-induced lung fibrosis, such as collagen,
hyarulonan, fibronectin, or proteoglycan. Decorin is a small proteo-
glycan and its core protein binds to TGF-β, leading to a neutraliza-
tion of the effect of TGF-β. Our immunohistochemical studies
showed a reduced expression of decorin (data not shown) and an
enhanced expression of TGF-β1 in the lesional skin of sclerosis at
4 wk. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
showed an increase of type I collagen, and biochemical assessment
revealed a significant increase of hydroxyproline contents in the
skin during the sclerotic stage. These results indicate that our mouse
model is characterized by sclerotic skin changes that are very similar
to scleroderma.
Recent studies suggest that cytokines released from macrophages
may play an important role in the development of BLM-induced
pulmonary fibrosis in animals. IL-1, IL-6, TGF-β, TNF-α, PDGF,
or insulin-like growth factor I (IGF-I) have been suggested to be
involved as effectors in the induction of experimental pulmonary
fibrosis (Piguet et al, 1989; Kovacs, 1991; Phan and Kunkel, 1992).
Focal release of cytokines is supposed to play a key role in fibroblast
proliferation and collagen synthesis. In particular, TGF-β is supposed
to play a crucial role in tissue fibrosis, which induces a rapid fibrotic
response when injected subcutaneously into newborn mice (Roberts
et al, 1986). TGF-β, which is able to upregulate its own synthesis
(Wahl et al, 1990), has been shown to stimulate human fibroblasts
to produce type I collagen in vitro (Varga et al, 1987). Multiple
actions of TGF-β include the strong induction of extracellular
matrix deposition by stimulating the production of matrix proteins,
inhibiting proteases that degrade matrix, and modulating the
expression of matrix receptors on the cell surface (Grande, 1997).
In BLM-induced pulmonary injury, TGF-β was maximally elevated
at 7 d after BLM administration (Khalit et al, 1989). Enhanced
expression of TGF-β mRNA occurs within the first 2 wk after
induction of lung injury (Hoyt and Lazo, 1988; Raghow et al,
1989). Alveolar macrophages obtained 7 d after BLM administration
secreted TGF-β1 in large quantities, whereas TGF-β2 and TGF-
β3 remained unchanged (Khalit et al, 1989). Recent studies
showed that TGF-β1 is ubiquitously produced by all cells, whereas
production of TGF-β2 is more selective (Phan et al, 1991). Our
study revealed that TGF-β1 mRNA was detected during the early
phase, whereas TGF-β2 mRNA was induced when sclerosis was
most prominent. TGF-β protein was expressed in the extracellular
matrix of the dermis most clearly in the sclerotic lesional skin at
4 wk. On the other hand, TNF-α gene expression was detected
during the early phase before sclerosis started. PDGF-AA was
constantly expressed during all stages. This discrepancy of cytokine
expression between lung and skin lesions may be due to the timing
examined, because lung fibrosis occurred earlier than cutaneous
sclerosis. In our model, TGF-β1 may have a primary role in the
pathogenesis of the sclerotic response and production of TGF-β2
starts as the sclerotic phase is completed. TGF-β2 mRNA has been
found in close proximity to fibroblasts expressing pro α I(I) collagen
near blood vessels in active SSc (Kulozik et al, 1990). Recent
findings showed that TGF-β isoforms may have different functions
and gene expressions during fibrotic processes (Shah et al, 1995;
Coker et al, 1997), and the triggering mechanism of the production
of TGF-β isoforms may be upregulated by other cytokines or by
autocrine regulation. Our results support the notion that TGF-β1
is a key regulatory molecule to initiate the activity of fibroblasts to
form cutaneous sclerosis.
Repeated subcutaneous injections of BLM induced autoanti-
bodies against nuclear components in our model. Autoimmune
mechanisms may be triggered by local administration of BLM. Our
mouse model develops cutaneous sclerosis with lung fibrosis and
autoantibodies, and may therefore provide a powerful tool for
examining the pathogenesis and therapeutic approach of scler-
oderma.
The study was supported in part by a grant of Scleroderma from the Japanese
Ministry of Public Welfare.
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